Related Experiment Videos
Beta-blocker therapy with metoprolol in the hyperventilation syndrome
Respiration; International Review of Thoracic Diseases
|January 1, 1981
Summary
Metoprolol effectively treats hyperventilation syndrome by reducing abnormal breathing patterns. This cardioselective beta-blocker improved patient ventilation responses in a clinical trial.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Background:
- Hyperventilation syndrome is characterized by abnormal breathing patterns.
- Understanding effective pharmacological interventions is crucial for patient management.
Purpose of the Study:
- To evaluate the efficacy of metoprolol in treating hyperventilation syndrome.
- To assess the impact of metoprolol on ventilatory response to CO2 and subjective patient experiences.
Main Methods:
- A double-blind, cross-over trial involving 16 patients with hyperventilation syndrome.
- Treatment arms included metoprolol (100 mg twice daily) and an identical placebo.
- Measurements included ventilatory response to CO2, vital capacity (VC), forced expiratory volume in 1 second (FEV1), and blood gas analysis.
Main Results:
- Metoprolol significantly reduced abnormal ventilation in patients compared to placebo (3/16 vs. 10/16, p < 0.01).
- End-tidal PCO2 increased by 3.86 mm Hg with metoprolol versus placebo (p = 0.0005).
- No significant differences were observed in respiratory rate, depth, base excess, or provocation test results.
Conclusions:
- The cardioselective beta-blocker metoprolol demonstrates utility in managing hyperventilation syndrome.
- Metoprolol appears to normalize ventilatory control in patients with this condition.